ISSN 1662-4009 (online)

ey0016.10-5 | (1) | ESPEYB16

10.5. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial

M Ballmann , H Dominique , MA Baroukh , D Staab , A Hebestreit , L Naehrlich , T Nickolay , N Prinz , RW Holl

To read the full abstract: Lancet Diabetes and Endocrinology 2018; 6: 114–121Cystic fibrosis (CF)-related diabetes (CFRD) impacts significantly on mortality and quality of life. Impaired glucose metabolism and CFRD are associated with poor weight and height gain and impaired lung function in children and adolescents (1). In that study, height and weight were lower in CF patients wit...